The agreement focuses on advancing Talem Therapeutics’ lead bispecific antibody, TATX-20, for treating hypoxic solid tumours. Credit: Sebastian Kaulitzki via Shutterstock.

ImmunoPrecise Antibodies, an AI-driven biotherapeutic research and technology company, has entered into a material transfer and evaluation agreement (MTEA) with Biotheus on bispecific antibodies to treat cancer.

The agreement focuses on the development of a new bispecific antibody therapy targeting hypoxic solid tumours using Talem Therapeutics’ TATX-20 lead candidate.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Under the MTEA, Biotheus will receive the specialised antibody asset from Talem Therapeutics, a subsidiary of ImmunoPrecise Antibodies and plans to utilise it alongside its proprietary technology to create new drugs for cancer.

These therapeutics aim to simultaneously target two different tumour markers, offering a potential breakthrough in cancer treatment, especially for tumours in oxygen-deprived environments.

Biotheus co-founder, chair, and CEO Xiaolin Liu said: “We are happy to enter into a collaboration with ImmunoPrecise Antibodies, a leading AI-driven biotech with powerful multi-omics modelling expertise.

See Also:

“Biotheus’ broad expertise in antibody discovery and development is powered by our fully integrated capabilities. By virtue of the AI-informed molecules spawned by ImmunoPrecise’s platform, we aim to develop novel bispecific antibodies with first-in-class potential and bring forth breakthrough therapies to cancer patients in the world.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The collaboration seeks to expedite the development of targeted therapies that could enhance patient outcomes for those with solid tumours.

Biotheus will assess the TATX-20 candidate, and upon successful evaluation, will advance the development of bispecific molecules. The goal is to produce a clinically effective product that can overcome the resistance of hypoxic solid tumours to existing treatments.

ImmunoPrecise Antibodies CEO Dr Jennifer Bath said: “Our collaboration aims to accelerate the creation of innovative cancer treatments, potentially leading to groundbreaking clinical outcomes.

“This agreement not only demonstrates the value of our AI-enhanced assets but also sets the stage for a long-term, mutually beneficial partnership that could transform the landscape of cancer therapeutics. We anticipate this collaboration will drive significant value for both companies and, most importantly, for patients in need of advanced treatment options.”

Biotheus announced an expansion of its strategic partnership with Hansoh Pharmaceutical Group in March 2024.

This expansion pertains to the development of bispecific antibody-drug conjugates targeting EGFR/cMET, marking a significant step forward in the company’s oncology and inflammatory disease portfolio.